Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 6.16Mono Pharmacare Ltd demonstrates a mixed financial performance. The company shows remarkable growth in revenue, operating profit, EPS, assets and net income. Profitability is generally strong, supported by good gross profit margins, ROCE, ROE, operating margin and net margin. The company's solvency position appears reasonable, indicating a balanced approach to debt and equity. However, liquidity is a concern, as reflected in lower cash and operating cash flow ratios. Efficiency metrics are weak, particularly in inventory and receivables management. The company's coverage ratios are also somewhat low, suggesting a limited ability to cover interest and dividend payments. Overall, Mono Pharmacare exhibits strong growth and profitability but needs to address its liquidity and efficiency challenges to ensure sustainable financial health.
Health Score : 6.16Mono Pharmacare Ltd demonstrates a mixed financial performance. The company shows remarkable growth in revenue, operating profit, EPS, assets and net income. Profitability is generally strong, supported by good gross profit margins, ROCE, ROE, operating margin and net margin. The company's solvency position appears reasonable, indicating a balanced approach to debt and equity. However, liquidity is a concern, as reflected in lower cash and operating cash flow ratios. Efficiency metrics are weak, particularly in inventory and receivables management. The company's coverage ratios are also somewhat low, suggesting a limited ability to cover interest and dividend payments. Overall, Mono Pharmacare exhibits strong growth and profitability but needs to address its liquidity and efficiency challenges to ensure sustainable financial health.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
42.75
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
42.75
P/B RATIO
0.48
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
N/A
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
0.00
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹8.55 as on Sep 1, 2026.
Growth Score : 10.00The company exhibits strong growth across multiple dimensions. This robust growth suggests that the company is successfully expanding its market presence and capitalizing on opportunities. The company is well-positioned for continued success and value creation.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2024 | Mar 2025 |
|---|---|---|
| Revenue Growth Rate | 351.85 | 37.7 |
| Operating Profit Growth Rate | 200 | 33.33 |
| Earnings Per Share (EPS) Growth | 142.11 | 26.81 |
| Asset Growth Rate | 28.57 | 35.8 |
| Net Income Growth Rate | 100 | 50 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medicamen Organics Ltd | 6.30 | -7.77 | Neutral | -3.75 | -2.50 | -4.02 |
| 2 | Mono Pharmacare Ltd | 6.16 | 42.75 | Neutral | 4.00 | 0.20 | N/A |
| 3 | JFL Life Sciences Ltd | 6.07 | 10.88 | Neutral | 12.00 | 1.94 | 6.00 |
| 4 | Walpar Nutritions Ltd | 5.29 | 9.89 | Neutral | 6.66 | 2.09 | 3.00 |
| 5 | Mangalam Drugs and Organics Ltd | 4.50 | -1.06 | Neutral | -15.00 | -27.68 | -44.00 |
| 6 | Lasa Supergenerics Ltd | 4.39 | -2.61 | Highly Undervalued | -7.00 | -6.80 | -34.00 |
| 7 | Sunrest Lifescience Ltd | 4.17 | 7.60 | Highly Undervalued | 10.21 | 3.60 | 8.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Mono Pharmacare Ltd is an Indian pharmaceutical company primarily engaged in the marketing, trading, and distribution of a wide range of pharmaceutical products. It supplies ethical drugs, OTC products, and medical devices to pharmacies, hospitals, and healthcare institutions, establishing itself as a key distributor in the Indian healthcare sector.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Mono Pharmacare Ltd's P/E ratio (TTM) is 42.75, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Mono Pharmacare Ltd's P/B ratio is 0.48, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Mono Pharmacare Ltd's P/S ratio is 0.87, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Mono Pharmacare Ltd's PEG ratio is 1.40.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Mono Pharmacare Ltd's EV/EBITDA ratio is 28.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Mono Pharmacare Ltd's ROE is 9.38%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Mono Pharmacare Ltd's ROA is 7.27%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Mono Pharmacare Ltd's ROCE is 11%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Mono Pharmacare Ltd's operating margin is 4.76%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Mono Pharmacare Ltd's net margin is 1.79%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Mono Pharmacare Ltd's current ratio is 2.07.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Mono Pharmacare Ltd's debt-to-equity ratio is 0.82.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Mono Pharmacare Ltd's interest coverage ratio is 2.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Mono Pharmacare Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Mono Pharmacare Ltd's EPS is 26.81.
(Source line: "Ratios as of 26 Sept 2026, based on last traded price of ₹8.55. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2021
Headquarters: Ahmedabad, Gujarat
Core Offerings: Pharmaceutical product distribution, Ethical drug marketing, OTC product supply, Medical device trading
Stock Listing: NSE (MONOPHARMA), BSE ({bse})
Promoter: Mr. Pankaj Kumar Pandya / Mr. Monish Pankajbhai Pandya
Founded in 2021, Mono Pharmacare Ltd commenced operations with a focus on pharmaceutical marketing and distribution. The company rapidly built a network for distributing various healthcare products. In September 2023, it successfully completed its SME IPO and listed on NSE Emerge, marking a significant milestone in its growth trajectory.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical Distribution | 100% | Operating Profit |
Pharmaceutical Distribution: Engaged in the wholesale distribution of a diverse portfolio of pharmaceutical products, including ethical drugs, over-the-counter (OTC) products, and medical devices, catering to a broad client base of pharmacies, hospitals, and healthcare institutions across various regions.
Therapeutic Areas: Specializes in distributing products across key therapeutic areas such as anti-infectives, pain management, gastrointestinal drugs, anti-allergic products, and cardiovascular medications, ensuring a comprehensive healthcare product offering.
Mr. Pankaj Kumar Pandya - Chairman & Whole-Time Director: With over two decades of experience in the pharmaceutical industry, he has been instrumental in shaping the company's marketing and distribution strategies and establishing its robust network. Mr. Monish Pankajbhai Pandya - Whole-Time Director: Brings valuable expertise to the company's strategic management and operational execution, contributing to its efficiency and market penetration.
No major subsidiaries reported.
Mono Pharmacare Ltd completed its SME Initial Public Offering (IPO) in September 2023, listing its shares on NSE Emerge.
The Mono Pharmacare Ltd share price today is ₹8.55 on NSE (MONOPHARMA), as of 26 Sept 2026.
As of 26 Sept 2026, Mono Pharmacare Ltd share price is ₹8.55, with previous close ₹8.55. Today's range is ₹8.55 to ₹8.55. The 52-week range is ₹7.50 to ₹20.95.
As of today, Mono Pharmacare Ltd's market cap is ₹0 crore (Small Cap).
Mono Pharmacare Ltd's current P/E ratio is 42.75, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 38.
Mono Pharmacare Ltd's current P/B ratio is 0.48.
Mono Pharmacare Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Mono Pharmacare Ltd's EPS (TTM) is ₹26.81.
Mono Pharmacare Ltd is an Indian pharmaceutical company primarily engaged in the marketing, trading, and distribution of a wide range of pharmaceutical products. It supplies ethical drugs, OTC products, and medical devices to pharmacies, hospitals, and healthcare institutions, establishing itself as a key distributor in the Indian healthcare sector.
Mono Pharmacare Ltd is promoted by Mr. Pankaj Kumar Pandya / Mr. Monish Pankajbhai Pandya, holding 56.72% as of 26 Sept 2026.
Mono Pharmacare Ltd is listed on NSE (MONOPHARMA) and BSE ({bse}). Its next quarterly results are expected on August 2024 (for Q1 FY25).
Adjusted Earnings Per Share (Adjusted EPS)
Debt Ratio
